论文部分内容阅读
目的:通过观察便秘型肠易激综合征(IBS-C)治疗前、后结肠黏膜TRPV1、PAR-2蛋白及其mRNA表达,探讨理气通便合剂干预IBS-C的可能机制。方法:30例符合诊断标准、纳入标准的IBS-C患者,予以理气通便合剂干预4周,采用荧光定量PCR、Western-blot技术检测治疗前后结肠TRPV1、PAR-2蛋白及其mRNA变化。结果:治疗前,IBS-C患者腹痛、腹部不适明显,伴见粪质坚硬,排便时间延长;予理气通便合剂干预14 d、28 d后,患者腹痛、腹部不适缓解,粪质变软,排便时间缩短,与治疗前比较,有统计学意义(P<0.05)。治疗前,IBS-C患者结肠黏膜TRPV1、PAR-2呈高表达变化;治疗后,TRPV1、PAR-2表达下降,有统计学意义(P<0.05)。结论:理气通便合剂可能通过降低TRPV1、PAR-2表达,发挥缩短排便时间,改善大便性状的效用。
Objective: To observe the expression of TRPV1 and PAR-2 protein and its mRNA in colonic mucosa of constipation-predominant irritable bowel syndrome (IBS-C) before and after treatment, and to explore the possible mechanism of Li Qi Tong Ban Mixture in intervention of IBS-C. Methods: Thirty patients with IBS-C were enrolled in the standard IBS-C group. The rats were infused with qi-invigorating and constipation mixture for 4 weeks. The changes of TRPV1 and PAR-2 mRNA and protein in colon were detected by real-time PCR and Western-blot. Results: Before treatment, IBS-C patients had abdominal pain and abdominal discomfort with hard and prolonged defecation. After 14 d and 28 d of treatment, patients with abdominal pain and abdominal discomfort were relieved, the fecal material became soft and defecate Time shortened, compared with before treatment, there was a statistically significant (P <0.05). Before treatment, the expression of TRPV1 and PAR-2 in colonic mucosa of IBS-C patients was highly expressed. After treatment, the expression of TRPV1 and PAR-2 decreased significantly (P <0.05). Conclusion: Li Qi Tong Ban Heji can reduce the expression of TRPV1 and PAR-2, shorten the defecation time and improve the stool traits.